The p53-estrogen receptor loop in cancer

Current Molecular Medicine

Volumn 13, Issue 8, 2013, Pages 1229-1240

  Berger, C ^a   Qian, Y ^a   Chen, X ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Estrogen receptor; Hormone dependent cancer; P53; Transcription factors

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; E1A ASSOCIATED P300 PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HYDROXYTAMOXIFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PACLITAXEL; PROTEIN MDM2; PROTEIN P21; PROTEIN P50; PROTEIN P53; SURVIVIN; SYNAPTOTAGMIN I; TAMOXIFEN;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; COLON CANCER; ENDOMETRIUM CANCER; ENZYME REGULATION; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UTERINE CERVIX CANCER;

ANIMALS; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884193685     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/15665240113139990065     Document Type: Review

References (150)

1. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75(4): 817-825.
2. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366(6456): 701-704.
3. Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-[alpha]/[beta] signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424(6948): 516-523.
4. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28(6): 622-629.
5. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2(1): a001008.
6. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250(4985): 1233-1238.
7. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 1989; 9(9): 3982-3991.
8. Pharoah PDP, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999; 80(12): 1968-1973.
9. Westhof G, Bader W, Greiner-Mai E, Hatzmann W. Comparison of cytosolic p53 protein levels in the female genital tract and breast, and their tumors. Tumour Biol 2000; 3(21): 123-134.
10. Dyson N, Hawley R, Miinger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243(4893): 934-937.
11. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63(6): 1129-1136.
12. Enmark E, Pelto-Huikko M, Grandien K, et al. Human Estrogen Receptor {beta}-Gene Structure, Chromosomal Localization, and Expression Pattern. J Clin Endocrinol Metab 1997; 82(12): 4258-4265.
13. Mosselman S, Polman J, Dijkema R. ER[beta]: Identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392(1): 49-53.
14. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors {alpha} and {beta}. Endocrinology 1997; 138(3): 863-870.
15. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986; 320(6058): 134-139.
16. Flouriot G, Brand H, Denger S, et al. Identification of a new isoform of the human estrogen receptor-alpha (hER-[alpha]) that is encoded by distinct transcripts and that is able to repress hER-[alpha] activation function 1. EMBO J 2000; 19(17): 4688-4700.
17. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 2005; 336(4): 1023-1027.
18. Shi L, Dong B, Li Z, et al. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 2009; 27(21): 3423-3429.
19. Moore JT, McKee DD, Slentz-Kesler K, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 1998; 247(1): 75-78.
20. Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA 2006; 103(35): 13162-13167.
21. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 2003; 22(32): 5011-5020.
22. Cerillo G, Rees A, Manchanda N, et al. The oestrogen receptor regulates NF[kappa]B and AP-1 activity in a cell-specific manner. J Steroid Biochem Mol Biol 1998; 67(2): 79-88.
23. Krishnan V, Wang X, Safe S. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem 1994; 269(22): 15912-15917.
24. Walker P, Germond J-E, Brown-Luedi M, Givel Fo, Wahli W. Sequence homologies in the region preceding the transcription initiation site of the liver estrogen-responsive vitellogenin and apo-VLDLII genes. Nucleic Acids Res 1984; 12(22): 8611-8626.
25. El-Ashry D, Chrysogelos SA, Lippman ME, Kern FG. Estrogen induction of TGF-alpha is mediated by an estrogen response element composed of two imperfect palindromes. J Steroid Biochem Mol Biol 1996; 59(3-4): 261-269.
26. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ER beta) of the human estrogen receptor modulates ER alpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140(12): 5566-78.
27. Hanstein B, Eckner R, DiRenzo J, et al. p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci USA 1996; 93(21): 11540-11545.
28. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 2000; 24(1): 145-155.
29. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351(9114): 1451-1467.
30. Bentzon N, During M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 2008; 122(5): 1089-1094.
31. Clarke R, Liu MC, Bouker KB, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003; 22(47): 7316-7339.
32. Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008; 456(7222): 663-666.
33. Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995; 345(8941): 29-30.
34. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993; 106(4): 1377-1388.
35. Long X, Nephew KP. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J Biol Chem 2006; 281(14): 9607-9615.
36. Ottaviano YL, Issa J-P, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994; 54(10): 2552-2555.
37. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. Hyperactivation of MAPK Induces Loss of ER{alpha} Expression in Breast Cancer Cells. Mol Endocrinol 2001; 15(8): 1344-1359.
38. Guo S, Sonenshein GE. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 2004; 24(19): 8681-8690.
39. Fu J, Zhang L, He T, et al. TWIST represses estrogen receptor-alpha expression by recruiting the NuRD protein complex in breast cancer cells. Int J Biol Sci 2012; 8(4): 522-532.
40. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011; 11(8): 597-608.
41. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004; 64(1): 423-428.
42. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001; 61(6): 2537-2541.
43. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004; 101(6): 1566-1571.
44. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001; 142(9): 4120-4130.
45. Tonetti DA, Rubenstein R, DeLeon M, et al. Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol 2003; 87(1): 47-55.
46. Hou YF, Yuan ST, Li HC, et al. ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 2004; 23(34): 5799-5806.
47. Shaaban AM, O'Neill PA, Davies MP, et al. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 2003; 27(12): 1502-1512.
48. Reich N, Levine AJ. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature 1984; 5955(308): 199-201.
49. Hurd C, Khattree N, Alban P, et al. Hormonal Regulation of the p53 Tumor Suppressor Protein in T47D Human Breast Carcinoma Cell Line. J Biol Chem 1995; 270(48): 28507-28510.
50. Hurd C, Khattree N, Dinda S, Alban P, Moudgil V. Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells. Oncogene 1997; 15(8): 991-995.
51. Fernandez-Cuesta L, Anaganti S, Hainaut P, Olivier M. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Int J Cancer 2010; 128(8): 1813-1821.
52. Weige CC, Allred KF, Armstrong CM, Allred CD. P53 mediates estradiol induced activation of apoptosis and DNA repair in non-malignant colonocytes. J Steroid Biochem Mol Biol 2012; 128(3-5): 113-120.
53. Fernández-Cuesta L, Anaganti S, Hainaut P, Olivier M. Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines. Breast Cancer Res Treat 2011; 125(1): 35-42.
54. Berger CE, Qian Y, Liu G, Chen H, Chen X. p53, a Target of Estrogen Receptor (ER) alpha, Modulates DNA Damage-induced Growth Suppression in ER-positive Breast Cancer Cells. J Biol Chem 2012; 287(36): 30117-30127.
55. Qin C, Nguyen T, Stewart J, Samudio I, Burghardt R, Safe S. Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor kappaB/CCAAT-binding transcription factor-1 complex. Mol Endocrinol 2002; 16(8): 1793-1809.
56. Hurd C, Dinda S, Khattree N, Moudgil VK. Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells. Oncogene 1999; 18(4): 1067-1072.
57. Gu G, Barone I, Gelsomino L, et al. Oldenlandia diffusa extracts exert antiproliferative and apoptotic effects on human breast cancer cells through ERalpha/Sp1-mediated p53 activation. J Cell Physiol 2012; 227(10): 3363-3372.
58. Okumura N, Saji S, Eguchi H, Hayashi S, Saji S, Nakashima S. Estradiol stabilizes p53 protein in breast cancer cell line, MCF-7. Jpn J Cancer Res 2002; 93(8): 867-873.
59. Molinari AM, Bontempo P, Schiavone EM, et al. Estradiol induces functional inactivation of p53 by intracellular redistribution. Cancer Res 2000; 60(10): 2594-2597.
60. Liu W, Konduri SD, Bansal S, et al. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 2006; 281(15): 9837-9840.
61. Yu C-L, Driggers P, Barrera-Hernandez G, Nunez SB, Segars JH, Cheng S-y. The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem Biophys Res Commun 1997; 239(2): 617-620.
62. Liu G, Schwartz JA, Brooks SC. Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res 2000; 60(7): 1810-1814.
63. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature 1997; 387(6635): 823-827.
64. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90(4): 595-606.
65. Liu G, Schwartz JA, Brooks SC. p53 Down-Regulates ER-Responsive Genes by Interfering with the Binding of ER to ERE. Biochem Biophys Res Commun 1999; 264(2): 359-364.
66. Konduri SD, Medisetty R, Liu W, et al. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci USA 2010; 107(34): 15081-15086.
67. Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res 2007; 67(16): 7746-7755.
68. Liu W, Ip MM, Podgorsak MB, Das GM. Disruption of estrogen receptor a-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy Breast Cancer Res Treat 2008; 115(1): 43-50.
69. Bailey ST, Shin H, Westerling T, Liu XS, Brown M. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci USA 2012; 109(44): 18060-18065.
70. Menendez D, Inga A, Resnick MA. Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences. Proc Natl Acad Sci USA 2010; 107(4): 1500-1505.
71. Ciribilli Y, Andreotti V, Menendez D, et al. The Coordinated P53 and Estrogen Receptor Cis-Regulation at an FLT1 Promoter SNP Is Specific to Genotoxic Stress and Estrogenic Compound. PLoS One 2010; 5(4): e10236.
72. Perillo B, Sasso A, Abbondanza C, Palumbo G. 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 2000; 20(8): 2890-2901.
73. Perillo B, Sasso A, Abbondanza C, Palumbo G. 17beta -Estradiol Inhibits Apoptosis in MCF-7 Cells, Inducing bcl-2 Expression via Two Estrogen-Responsive Elements Present in the Coding Sequence. Mol Cell Biol 2000; 20(8): 2890-2901.
74. Thomas CG, Strom A, Lindberg K, Gustafsson JA. Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G(2)/M checkpoint signaling. Breast Cancer Res Treat 2011; 127(2): 417-427.
75. Cotrim CZ, Fabris V, Doria ML, et al. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells. Oncogene 2013; 32(19): 2390-2402.
76. Hartman J, Edvardsson K, Lindberg K, et al. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 2009; 69(15): 6100-6106.
77. Hsu HH, Cheng SF, Wu CC, et al. Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. Chin J Physiol 2006; 49(2): 110-116.
78. Lewandowski SA, Thiery J, Jalil A, Leclercq G, Szczylik C, Chouaib S. Opposite effects of estrogen receptors alpha and beta on MCF-7 sensitivity to the cytotoxic action of TNF and p53 activity. Oncogene 2005; 24(30): 4789-4798.
79. Klein-Hitpass L, Ryffel GU, Heitlinger E, Cato ACB. A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor. Nucleic Acids Res 1988; 16(2): 647-63.
80. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-Regulation of bcl-2 by p53 in Breast Cancer Cells. Cancer Res 1994; 54(8): 2095-2097.
81. Jin W, Chen Y, Di GH, et al. Estrogen receptor (ER) beta or p53 attenuates ERalpha-mediated transcriptional activation on the BRCA2 promoter. J Biol Chem 2008; 283(44): 29671-29680.
82. Kunz C, Pebler S, Otte Jr, von der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res 1995; 23(18): 3710-3717.
83. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 1991; 88(17): 7605-7609.
84. Teixeira C, Reed JC, Pratt MAC. Estrogen Promotes Chemotherapeutic Drug Resistance by a Mechanism Involving Bcl-2 Proto-Oncogene Expression in Human Breast Cancer Cells. Cancer Res 1995; 55(17): 3902-3907.
85. Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, Ferragut JA, Saceda M. Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol 2004; 180(3): 497-504.
86. Shirley SH, Rundhaug JE, Tian J, et al. Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res 2009; 69(8): 3405-3414.
87. MacMahon B, Cole P, Lin TM, et al. Age at first birth and breast cancer risk. Bull World Health Organ 1970; 43(2): 209-221.
88. Marchant J. Influence of pregnancy and lactation on the incidence of mammary carcinoma induced with methylcholanthrene in female mice of the IF strain. J Pathol Bacteriol 1955; 70(2): 415-418.
89. Medina D, Smith GH. Chemical Carcinogen-Induced Tumorigenesis in Parous, Involuted Mouse Mammary Glands. J Natl Cancer Inst 1999; 91(11): 967-969.
90. Moon R. Relationship between previous reproductive history and chemically induced mammary cancer in rats. Int J Cancer 1969; 4(3): 312-317.
91. Becker KA, Lu S, Dickinson ES, et al. Estrogen and progesterone regulate radiation-induced p53 activity in mammary epithelium through TGF-[beta]-dependent pathways. Oncogene 2005; 24(42): 6345-6353.
92. Huggins C, Moon RC, Morii S. Extinction of experimental mammary cancer, I. estradiol-17β3 and progesterone. Proc Natl Acad Sci USA 1962; 48(3): 379-386.
93. Sivaraman L, Conneely OM, Medina D, O'Malley BW. p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc Natl Acad Sci USA 2001; 98(22): 12379-12384.
94. Díaz-Cruz ES, Furth PA. Deregulated Estrogen Receptor alpha and p53 Heterozygosity Collaborate in the Development of Mammary Hyperplasia. Cancer Res 2010; 70(10): 3965-3974.
95. Shai A, Pitot HC, Lambert PF. p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res 2008; 68(8): 2622-2631.
96. Lønning PE, Knappskog S, Staalesen V, Chrisanthar R, Lillehaug JR. Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol 2007; 18(8): 1293-1306.
97. Banin S, Moyal L, Shieh SY, et al. Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage. Science 1998; 281(5383): 1674-1677.
98. Phelan CM, Borg A, Cuny M, et al. Consortium Study on 1280 Breast Carcinomas: Allelic Loss on Chromosome 17 Targets Subregions Associated with Family History and Clinical Parameters. Cancer Res 1998; 58(5): 1004-1012.
99. Callahan R, Cropp C, Merlo G, et al. Genetic and molecular heterogeneity of breast cancer cells. Clin Chim Acta 1993; 217(1): 63-73.
100. Osborne RJ, Hamshere MG. A Genome-wide Map Showing Common Regions of Loss of Heterozygosity/Allelic Imbalance in Breast Cancer. Cancer Res 2000; 60(14): 3706-3712.
101. Cunningham JM, Ingle JN, Jung SH, et al. p53 Gene Expression in Node-Positive Breast Cancer: Relationship to DNA Ploidy and Prognosis. J Natl Cancer Inst 1994; 86(24): 1871-1873.
102. Elledge RM, Green S, Howes L, et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol 1997; 15(5): 1916-22.
103. Gretarsdottir S, Tryggvadottir L, Jonasson J, et al. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer 1996; 74(4): 555-561.
104. Lipponen P, Ji H, Aaltomaa S, Syrjänen S, Syrjänen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 1993; 55(1): 51-56.
105. MacGrogan G, Bonichon F, de Mascarel I, et al. Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 1995; 36(1): 71-81.
106. Olivier M, Langerød A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006; 12(4): 1157-1167.
107. Love RR, Mazess RB, Barden HS, et al. Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer. N Engl J Med 1992; 326(13): 852-856.
108. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor Dynamics and Sufficiency in Estrogen Receptor-Regulated Transcription. Cell 2000; 103(6): 843-852.
109. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The Partial Agonist Activity of Antagonist-Occupied Steroid Receptors Is Controlled by a Novel Hinge Domain-Binding Coactivator L7/SPA and the Corepressors N-CoR or SMRT. Mol Endocrinol 1997; 11(6): 693-705.
110. Frasor J, Chang EC, Komm B, et al. Gene Expression Preferentially Regulated by Tamoxifen in Breast Cancer Cells and Correlations with Clinical Outcome. Cancer Res 2006; 66(14): 7334-7340.
111. Love RR. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol 1989; 7(6): 803-815.
112. Ichikawa A, Ando J, Suda K. G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells. Hum Cell 2008; 21(2): 28-37.
113. Varma H, Conrad SE. Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain. Oncogene 2000; 19(41): 4746-4753.
114. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995; 1(10): 1029-1034.
115. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA 2006; 295(14): 1658-1667.
116. Planas-Silva MD, Weinberg RA. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 1997; 17(7): 4059-4069.
117. Prall OWJ, Sarcevic B, Musgrove EA, Watts CKW, Sutherland RL. Estrogen-induced Activation of Cdk4 and Cdk2 during G1-S Phase Progression Is Accompanied by Increased Cyclin D1 Expression and Decreased Cyclin-dependent Kinase Inhibitor Association with Cyclin E-Cdk2. J Biol Chem 1997; 272(16): 10882-1094.
118. Watts CK, Brady A, Sarcevic B, deFazio A, Musgrove EA, Sutherland RL. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 1995; 9(12): 1804-1813.
119. Berns EMJJ, Foekens JA, Vossen R, et al. Complete Sequencing of TP53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer. Cancer Res 2000; 60(8): 2155-2162.
120. Archer S, Eliopoulos A, Spandidos D, et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995; 72(5): 1259-1266.
121. Lim LY, Vidnovic N, Ellisen LW, Leong CO. Mutant p53 mediates survival of breast cancer cells. Br J Cancer 2009; 101(9): 1606-1612.
122. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities. J Natl Cancer Inst 2005; 97(14): 1066-1071.
123. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003; 16(1): 1-17.
124. Moreno V, Bosch FX, Muñoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359(9312): 1085-1092.
125. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci USA 2005; 102(7): 2490-2495.
126. Park JS, Rhyu JW, Kim CJ, et al. Neoplastic change of squamo-columnar junction in uterine cervix and vaginal epithelium by exogenous estrogen in hpv-18 URR E6/E7 transgenic mice. Gynecol Oncol 2003; 89(3): 360-368.
127. Chung SH, Wiedmeyer K, Shai A, Korach KS, Lambert PF. Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res 2008; 68(23): 9928-9934.
128. Au WW, Abdou-Salama S, Al-Hendy A. Inhibition of growth of cervical cancer cells using a dominant negative estrogen receptor gene. Gynecol Oncol 2007; 104(2): 276-280.
129. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 2003; 63(16): 4862-4871.
130. Shai A, Brake T, Somoza C, Lambert PF. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res 2007; 67(4): 1626-1635.
131. Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999; 91(19): 1654-1662.
132. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86(7): 527-537.
133. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 2000; 356(9233): 881-887.
134. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62(1): 10-29.
135. Stygar D, Muravitskaya N, Eriksson B, Eriksson H, Sahlin L. Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus. Reprod Biol Endocrinol 2003; 1: 40.
136. Hoogendoorn WE, Hollema H, van Boven HH, et al. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res Treat 2008; 112(1): 99-108.
137. Fujiwara K, Enomoto T, Fujita M, et al. Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma. Oncol Rep 2008; 19(5): 1293-1298.
138. Niwa K, Morishita S, Hashimoto M, et al. Effects of Tamoxifen on Endometrial Carcinogenesis in Mice. Jpn J Cancer Res 1998; 89(5): 502-509.
139. Maeda K, Tsuda H, Hashiguchi Y, et al. Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer. Hum Pathol 2002; 33(4): 386-391.
140. Niwa K, Murase T, Morishita S, Hashimoto M, Itoh N, Tamaya T. p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status. Cancer Detect Prev 1999; 23(2): 147-154.
141. Froggatt NJ, Green J, Brassett C, et al. A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. J Med Genet 1999; 36(2): 97-102.
142. English MA, Stewart PM, Hewison M. Estrogen metabolism and malignancy: analysis of the expression and function of 17beta-hydroxysteroid dehydrogenases in colonic cancer. Mol Cell Endocrinol 2001; 171(1-2): 53-60.
143. Weiss N, Daling J, Chow W. Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. J Natl Cancer Inst 1981; 67(1): 57-60.
144. Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S. Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control 1997; 8(2): 146-158.
145. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350(10): 991-1004.
146. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor beta in colon cancer cells. Biochem Biophys Res Commun 1999; 261(2): 521-527.
147. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of Estrogen Receptor (ER) Subtypes and ERbeta Isoforms in Colon Cancer. Cancer Res 2001; 61(2): 632-640.
148. Konstantinopoulos PA, Kominea A, Vandoros G, et al. Oestrogen receptor beta (ER[beta]) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 2003; 39(9): 1251-8.
149. Saleiro D, Murillo G, Benya RV, Bissonnette M, Hart J, Mehta RG. Estrogen receptor-beta protects against colitis-associated neoplasia in mice. Int J Cancer 2012; 131(11): 2553-2561.
150. Martineti V, Picariello L, Tognarini I, et al. ERbeta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr Relat Cancer 2005; 12(2): 455-469.